Consort Medical plc (LON:CSRT) insider Paul Hayes purchased 13 shares of Consort Medical plc stock in a transaction that occurred on Monday, August 7th. The stock was purchased at an average cost of GBX 1,100 ($14.32) per share, for a total transaction of £143 ($186.22).

Paul Hayes also recently made the following trade(s):

  • On Tuesday, June 20th, Paul Hayes purchased 4,000 shares of Consort Medical plc stock. The stock was purchased at an average cost of GBX 1,094 ($14.25) per share, for a total transaction of £43,760 ($56,986.59).

Shares of Consort Medical plc (LON:CSRT) opened at 1093.00 on Thursday. The firm has a 50-day moving average price of GBX 1,056.56 and a 200 day moving average price of GBX 1,034.88. Consort Medical plc has a 12-month low of GBX 960.00 and a 12-month high of GBX 1,180.00. The company’s market capitalization is GBX 534.62 million.

The business also recently declared a dividend, which will be paid on Friday, October 27th. Stockholders of record on Thursday, September 21st will be issued a GBX 13.21 ($0.17) dividend. The ex-dividend date of this dividend is Thursday, September 21st. This is an increase from Consort Medical plc’s previous dividend of $7.09. This represents a dividend yield of 1.3%.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/10/consort-medical-plc-csrt-insider-acquires-143-in-stock.html.

Several brokerages recently weighed in on CSRT. N+1 Singer reaffirmed a “buy” rating and issued a GBX 1,125 ($14.65) price target on shares of Consort Medical plc in a research note on Thursday, June 15th. Shore Capital reissued a “buy” rating on shares of Consort Medical plc in a report on Thursday, June 15th. Numis Securities Ltd reissued a “hold” rating and issued a GBX 1,084 ($14.12) target price on shares of Consort Medical plc in a report on Thursday, June 15th. Panmure Gordon reissued a “buy” rating and issued a GBX 1,145 ($14.91) target price on shares of Consort Medical plc in a report on Thursday, June 15th. Finally, Investec reissued a “buy” rating and issued a GBX 1,165 ($15.17) target price on shares of Consort Medical plc in a report on Thursday, June 15th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Consort Medical plc presently has a consensus rating of “Buy” and an average target price of GBX 1,153.17 ($15.02).

Consort Medical plc Company Profile

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.